Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer

被引：0
|
作者：
Makoto Sudo
Tan Min Chin
Seiichi Mori
Ngan B. Doan
Jonathan W. Said
Makoto Akashi
H. Phillip Koeffler
机构：
[1] National University of Singapore,Cancer Science Institute
[2] National University Hospital,Department of Hematology and Oncology
[3] The Cancer Institute,Department of Cancer Genomics
[4] Japanese Foundation for Cancer Research,Department of Pathology and Laboratory Medicine
[5] University of California,Research Center for Radiation Emergency
[6] National Institute of Radiological Sciences,Division of Hematology and Oncology
[7] Cedars-Sinai Medical Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2013年 / 71卷
关键词：
Non-small cell lung cancer (NSCLC); Tyrosine kinase inhibitor (TKI); EGFR; 17-DMAG; Belinostat; Combination chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1325 / 1334
页数：9
相关论文
共 50 条
  • [41] Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells
    Li, Wang
    Wang, Heyong
    Yang, Yan
    Zhao, Tian
    Zhang, Zhixiong
    Tian, Ye
    Shi, Zhaomie
    Peng, Xiaojun
    Li, Fei
    Feng, Yonghong
    Zhang, Lei
    Jiang, Gening
    Zhang, Fan
    PROTEOMICS, 2018, 18 (15)
  • [42] Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
    Araki, Takuya
    Yashima, Hideaki
    Shimizu, Kimihiro
    Aomori, Tohru
    Hashita, Tadahiro
    Kaira, Kyoichi
    Nakamura, Tomonori
    Yamamoto, Koujirou
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [43] Gefitinib (Iressa) trials in non-small cell lung cancer
    Johnson, DH
    LUNG CANCER, 2003, 41 : S23 - S28
  • [44] Gefitinib: an "orphan" drug for non-small cell lung cancer
    Ziogas, Dimitrios C.
    Liontos, Michalis
    Kyriazoglou, Anastasios
    Tsironis, Georgios
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (11): : 899 - 906
  • [45] Gefitinib (Iressa) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78
  • [46] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [47] RETRACTED: miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog (Retracted Article)
    Bi, Mingjun
    Chen, Wei
    Yu, Hongmei
    Wang, Jinxiu
    Ding, Fang
    Tang, Dong Jing
    Tang, Cuiyan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 480 (03) : 369 - 374
  • [48] Deubiquitination of epidermal growth factor receptor by ubiquitin-specific peptidase 54 enhances drug sensitivity to gefitinib in gefitinib-resistant non-small cell lung cancer cells
    Kim, Mi Seong
    Kim, Min Seuk
    PLOS ONE, 2025, 20 (04):
  • [49] The growth inhibitory effect of paclitaxel on gefitinib-resistant non-small cell lung cancer (NSCLC) cells during the COVID-19 pandemic.
    Mohiuddin, Md
    Kimura, Hideharu
    Sone, Takashi
    Watanabe, Satoshi
    Matsuoka, Hiroki
    Saeki, Keigo
    Terada, Nanao
    Abo, Miki
    Kasahara, Kazuo
    CANCER RESEARCH, 2021, 81 (13)
  • [50] Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer
    Yang, Qi
    Chen, Wenyu
    Xu, Yufeng
    Lv, Xiaodong
    Zhang, Ming
    Jiang, Hao
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2018, 356 : 1 - 7
12345